Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
That is, compared to insulin, 57 and 30 patients would need to be treated with a GLP-1RA for a mean of 2.3 years to prevent one case of all-cause mortality and hospitalized hypoglycemia, respectively, which would cost US$54,851 and US$29,115 per case of all-cause mortality and hospitalized hypoglycemia prevented, respectively, from the payer perspective, and would save US$19,391 and US$10,293, respectively, from the healthcare sector perspective
Drucker and Habener showed that small quantities of laboratory-synthesized GLP-1 could trigger insulin
Injection Technique Clean hands and workspace before handling any supplies
You can read the full article at Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial PMC (nih.gov)
US$ 27.91
US$ 28.67
US$ 25.43
US$ 24.91
US$ 29.86
US$ 21.46
US$ 23.80
US$ 26.88
US$ 28.83
US$ 24.53
US$ 25.32
